Dick Sundh
About Dick Sundh
Dick Sundh serves as the Head of ACE (Australia, Canada & Europe) at Kite Pharma, a position he has held since 2020. He has extensive experience in the pharmaceutical industry, having worked in various leadership roles at AstraZeneca, Gilead Sciences, and St. Jude Medical.
Work at Kite Pharma
Dick Sundh serves as the Head of ACE (Australia, Canada & Europe) at Kite Pharma, a role he has held since 2020. In this position, he oversees operations and strategic initiatives across three key regions. Prior to this role, he was the Head of Europe at Kite Pharma from 2018 to 2020, where he focused on expanding the company's presence and market share in European markets.
Previous Experience in the Pharmaceutical Industry
Before joining Kite Pharma, Dick Sundh held several significant positions in the pharmaceutical sector. He worked at AstraZeneca Russia in various roles, including Marketing & Sales Director for Central and Eastern Europe from 2006 to 2007, and Vice President of Marketing & Sales for Russia & CIS from 2007 to 2008. He also served as the National Sales Manager and Regional Sales Manager at AstraZeneca Russia from 1999 to 2006. Additionally, he was the General Manager for Gilead Sciences in the Nordics from 2012 to 2014 and later as Vice President for the EMEA Region West from 2015 to 2018.
Education and Qualifications
Dick Sundh completed his Bachelor’s degree at Örebro University from 1988 to 1992. He also attended Ållebergsgymnasiet Falköping from 1981 to 1986. His educational background has provided him with a strong foundation for his extensive career in the pharmaceutical industry.
Leadership Roles at St. Jude Medical
At St. Jude Medical, Dick Sundh held multiple leadership roles. He was the Managing Director for Sweden and Area Manager for Scandinavia from 2008 to 2010. Following this, he served as Vice President for EMEAC Emerging Markets & Distributors from 2010 to 2012. His experience at St. Jude Medical contributed to his expertise in managing diverse markets and driving sales growth.